NORROY BIOSCIENCE

Description

Headquarters: CN

Structure of NORROY BIOSCIENCE

NORROY BIOSCIENCE

Company

3 connections

ConstraintsRegulation and exposure

OwnProducts and technology

DownstreamCustomers

Relationship began2026Unsorted nodes

NORROY BIOSCIENCECompany · 3 connections

Layer 1

DownstreamCustomers1

OwnProducts and technology1

ConstraintsRegulation and exposure1

Place in the network

No. 16227 of 101252top 17%down 7649 places this week

2 direct links

In a group of 9 closely linked entities, around

PharmaLogic Holdings Corp.Lantheus Holdings Inc.Radiopharmaceuticals Thomas Tulip

Weighted by public relations with evidence, recomputed daily.

How is it connected to …

Relations

Money between companies

Who invests in, owns, acquires or finances whom, from the relations AiSeek holds with evidence.

From NORROY BIOSCIENCE

automation technologiesinvests in

Lines show that a relation exists and which way it points; their thickness carries no amount. Dots only move to show the direction.

Arrows show the direction of the relationship. Filter to focus on a business area.

Thomas Tulippart of →NORROY BIOSCIENCE
Person · Thomas TulipEvidence 1
Fact90%
View evidence
- CompanyPR Newswire news releases2026-11-05 18:00
  Chief Business Officer (CBO) of NORROY
  View source
NORROY BIOSCIENCElocated in →China
Geography · ChinaEvidence 1
Fact90%
View evidence
- CompanyPR Newswire news releases2026-11-05 18:00
  WUXI, China
  View source
NORROY BIOSCIENCEinvests in →automation technologies
Technology · automation technologiesEvidence 1
Fact90%
View evidence
- CompanyPR Newswire news releases2026-11-05 18:00
  Through continued R&D and investment in radiopharmaceutical innovation, clinical development and automation technologies, NORROY aims to advance its pipelines and strengthen collaboration with global partners to support the development of nuclear medicine and radiotheranostics.
  View source
NORROY BIOSCIENCEoperates in →Radiopharmaceuticals
Industry · RadiopharmaceuticalsEvidence 1
Fact90%
View evidence
- CompanyPR Newswire news releases2026-11-05 18:00
  a late-stage clinical biotechnology company focused on innovative targeted radiopharmaceuticals
  View source

Showing 1 to 4 of 4

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1

invests inautomation technologies

Through continued R&D and investment in radiopharmaceutical innovation, clinical development and automation technologies, NORROY aims to advance its pipelines and strengthen collaboration with global partners to support the development of nuclear medicine and radiotheranostics.